FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996002615> ?p ?o ?g. }

• W2996002615 endingPage "753" @default.
• W2996002615 startingPage "741" @default.
• W2996002615 abstract "Previous studies have investigated magnetic resonance imaging-targeted biopsy (MRI-TBx) on the detection for prostate cancer (PCa). Prostate Imaging Reporting and Data System (PI-RADS), as a standardized MRI reporting system, has widely been used in the management of PCa. However, basing the PI-RADS score, the comparability between MRI-TBx and transrectal ultrasound-guided biopsy (TRUS-Bx) in diagnosing PCa remained inconsistent or even controversial. Thus, this systematic meta-analysis aimed to assess the value of PI-RADS in sifting better prostate biopsy method.A meta-analysis including 10 articles was performed. In these included studies, biopsy-naive subjects with concerning PSA levels and/or an abnormal digital rectal examination (DRE) were consecutively enrolled by referral from urologists. All subjects underwent multiparameter MRI (mpMRI) prostate and the results were scored independently by PI-RADS. Subjects with equivocal (PI-RADS 3) and intermediate/high-risk (PI-RADS 4/5) lesions underwent MRI-TBx and followed by TRUS-Bx performed by a urologist. The online databases PubMed, Embase and Web of Science were searched to find all correlated articles until October 1st, 2019. Data were pooled by odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the associations. Subgroup analyses were conducted based on Gleason score.Overall, 10 studies were included in this meta-analysis from January, 2015 to June, 2019. In the comparison of the detection of MRI-TBx and TRUS-Bx in PCa patients, TRUS-Bx had a significant advantage in overall PCa detection compared with MRI-TBx (OR =0.78, 95% CI: 0.62-0.98) in PI-RADS 3. Basing subgroup analysis of Gleason score (csPCa: Gleason score ≥7; non-csPCa: Gleason score <7), a summary analysis of the detection rate of csPCa showed that no significant difference was found (OR =0.82, 95% CI: 0.58-1.16); Meanwhile, no significant difference in non-csPCa patients was also detected (OR =0.83, 95% CI: 0.53-1.28). In PI-RADS 4 or 5, no significant results were detected between MRI-TBx and TRUS-Bx (OR =0.96, 95% CI: 0.87-1.06) for overall PCa detection. The stratification analyses by Gleason score found that TRUS-Bx had an advantage over MRI-TBx in non-csPCa patients (OR =0.76, 95% CI: 0.60-0.98); However, there was no significant difference in the detection rate of csPCa (OR =1.05, 95% CI: 0.93-1.20).This meta-analysis indicated that using TRUS-Bx was better than MRI-TBx for the diagnosis of PCa in PI-RADS 3; Besides, TRUS-Bx have an advantage over MRI-TBx in the detection for non-csPCa in PI-RADS 4 or 5. Therefore, PI-RADS could be used as a MRI evaluation system in the selection of prostate biopsy." @default.
• W2996002615 created "2019-12-26" @default.
• W2996002615 creator A5005288619 @default.
• W2996002615 creator A5010431622 @default.
• W2996002615 creator A5033441324 @default.
• W2996002615 creator A5043155449 @default.
• W2996002615 creator A5044774734 @default.
• W2996002615 creator A5052966060 @default.
• W2996002615 creator A5053187190 @default.
• W2996002615 creator A5053217938 @default.
• W2996002615 creator A5067191567 @default.
• W2996002615 creator A5070718477 @default.
• W2996002615 creator A5087798680 @default.
• W2996002615 creator A5088695098 @default.
• W2996002615 date "2019-12-01" @default.
• W2996002615 modified "2023-10-16" @default.
• W2996002615 title "Comparison of prostate cancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA ≥4 ng/mL: a systematic review and meta-analysis" @default.
• W2996002615 cites W1133272649 @default.
• W2996002615 cites W1494521255 @default.
• W2996002615 cites W1940779952 @default.
• W2996002615 cites W1981989535 @default.
• W2996002615 cites W2003854483 @default.
• W2996002615 cites W2007872832 @default.
• W2996002615 cites W2010403340 @default.
• W2996002615 cites W2036612642 @default.
• W2996002615 cites W2080725537 @default.
• W2996002615 cites W2081830150 @default.
• W2996002615 cites W2095011839 @default.
• W2996002615 cites W2095761465 @default.
• W2996002615 cites W2110881680 @default.
• W2996002615 cites W2115726304 @default.
• W2996002615 cites W2123395369 @default.
• W2996002615 cites W2124539070 @default.
• W2996002615 cites W2162670954 @default.
• W2996002615 cites W2164364841 @default.
• W2996002615 cites W2336160181 @default.
• W2996002615 cites W2362416355 @default.
• W2996002615 cites W2511755939 @default.
• W2996002615 cites W2520646350 @default.
• W2996002615 cites W2545704016 @default.
• W2996002615 cites W2561921160 @default.
• W2996002615 cites W2570217086 @default.
• W2996002615 cites W2579469095 @default.
• W2996002615 cites W2611333925 @default.
• W2996002615 cites W2734348020 @default.
• W2996002615 cites W2743732644 @default.
• W2996002615 cites W2764317271 @default.
• W2996002615 cites W2765352993 @default.
• W2996002615 cites W2765809915 @default.
• W2996002615 cites W2790486088 @default.
• W2996002615 cites W2792902150 @default.
• W2996002615 cites W2799891735 @default.
• W2996002615 cites W2808164498 @default.
• W2996002615 cites W2900548778 @default.
• W2996002615 cites W2902322634 @default.
• W2996002615 cites W2957236657 @default.
• W2996002615 doi "https://doi.org/10.21037/tau.2019.12.03" @default.
• W2996002615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6987594" @default.
• W2996002615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32038971" @default.
• W2996002615 hasPublicationYear "2019" @default.
• W2996002615 type Work @default.
• W2996002615 sameAs 2996002615 @default.
• W2996002615 citedByCount "6" @default.
• W2996002615 countsByYear W29960026152020 @default.
• W2996002615 countsByYear W29960026152021 @default.
• W2996002615 countsByYear W29960026152022 @default.
• W2996002615 crossrefType "journal-article" @default.
• W2996002615 hasAuthorship W2996002615A5005288619 @default.
• W2996002615 hasAuthorship W2996002615A5010431622 @default.
• W2996002615 hasAuthorship W2996002615A5033441324 @default.
• W2996002615 hasAuthorship W2996002615A5043155449 @default.
• W2996002615 hasAuthorship W2996002615A5044774734 @default.
• W2996002615 hasAuthorship W2996002615A5052966060 @default.
• W2996002615 hasAuthorship W2996002615A5053187190 @default.
• W2996002615 hasAuthorship W2996002615A5053217938 @default.
• W2996002615 hasAuthorship W2996002615A5067191567 @default.
• W2996002615 hasAuthorship W2996002615A5070718477 @default.
• W2996002615 hasAuthorship W2996002615A5087798680 @default.
• W2996002615 hasAuthorship W2996002615A5088695098 @default.
• W2996002615 hasBestOaLocation W29960026151 @default.
• W2996002615 hasConcept C121608353 @default.
• W2996002615 hasConcept C126322002 @default.
• W2996002615 hasConcept C126838900 @default.
• W2996002615 hasConcept C143409427 @default.
• W2996002615 hasConcept C143753070 @default.
• W2996002615 hasConcept C156957248 @default.
• W2996002615 hasConcept C2775934546 @default.
• W2996002615 hasConcept C2776235491 @default.
• W2996002615 hasConcept C2780101318 @default.
• W2996002615 hasConcept C2780192828 @default.
• W2996002615 hasConcept C2781217009 @default.
• W2996002615 hasConcept C71924100 @default.
• W2996002615 hasConcept C95190672 @default.
• W2996002615 hasConceptScore W2996002615C121608353 @default.
• W2996002615 hasConceptScore W2996002615C126322002 @default.
• W2996002615 hasConceptScore W2996002615C126838900 @default.
• W2996002615 hasConceptScore W2996002615C143409427 @default.
• W2996002615 hasConceptScore W2996002615C143753070 @default.

• next